ID-genomics on inferagen
Tuberculosis drug resistance, AMR surveillance, viral typing, and outbreak investigation — pipelines for Indian public-health and clinical labs.
Clinical context
India is the world's largest TB market — and the WHO is moving toward genomic drug-susceptibility testing as the standard of care. inferagen runs validated pipelines for Mtb resistance, AMR surveillance for ESKAPE pathogens, and SARS-CoV-2/respiratory virus typing.
What we deliver
On inferagen.
- Mycobacterium tuberculosis whole-genome resistance prediction (WHO catalogue v2)
- AMR gene detection across ESKAPE pathogens
- Viral typing and lineage assignment (SARS-CoV-2, influenza, dengue)
- Outbreak phylogenetics with SNP-distance trees
- Public-health-grade reporting (NCDC/IDSP-aligned)
Sample report
See exactly what your clinician will receive.
An anonymized PDF for this exact test type — patient summary, clinician summary, and ACMG detail. PII removed.
Download sample reportPricing
Credits per sample.
200–800 credits per sample (~₹4,000 – ₹16,000).
See full pricing & credit consumption →Design-partner programme
First design partners running this in beta — talk to us to be next.
We're onboarding a small group of labs for this test type. Design partners get free credits, white-glove onboarding, and direct input into our roadmap.
Apply to be a design partner →